



Ind-Swift Laboratories Limited

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2025

Date: 4th November, 2025

**The President
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001**

**The Vice President,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051**

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

SUBJECT: UPDATE ON LISTING OF SHARES ALLOTTED PURSUANT TO THE SCHEME OF AMALGAMATION

Dear Sir/Ma'am,

In continuation to our intimation dated August 25, 2025, regarding the allotment of equity shares of Ind-Swift Laboratories Limited to the eligible shareholders of Ind-Swift Limited pursuant to the approved Scheme of Amalgamation, we wish to update all stakeholders on the latest status of the credit of these shares in the Demat account of the respective shareholders and the beginning of trading of these shares.

Post-allotment, the Company filed listing applications with both the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on September 12, 2025, seeking approval for the listing of the newly allotted equity shares.

We are pleased to inform you that NSE has granted its approval for listing on October 10, 2025. The approval from BSE is currently awaited. All requisite documents and clarifications have already been submitted, and the Company is in regular communication with the exchange to expedite the process.

Upon receipt of listing approval from BSE (which is under final review and expected shortly), the Company will undertake the necessary corporate action for credit of these shares to the Demat account of the respective shareholders and subsequently apply for trading approval. Once trading approval is granted, shareholders will be able to trade in the newly allotted equity shares of Ind-Swift Laboratories Limited.

The Company remains fully committed to ensuring compliance with all applicable regulatory requirements and will continue to keep shareholders informed of any further developments in this regard.

For **IND-SWIFT LABORATORIES LTD.**

**PARDEEP VERMA
VP-CORPORATE AFFAIRS &
COMPANY SECRETARY**

